ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08575
0,00%
Bitcoin
67.596,87
0,17%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kiromic BioPharma Inc (KRBP)

  7. Kiromic BioPharma Inc (KRBP) News

KRBP

Kiromic BioPharma (KRBP)

Kiromic BioPharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KRBP
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202414h00Business WireKiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
22/05/202423h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
21/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
20/05/202423h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:KRBPKiromic BioPharma Inc
20/05/202414h00Business WireKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteNASDAQ:KRBPKiromic BioPharma Inc
20/05/202412h29Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KRBPKiromic BioPharma Inc
17/05/202422h43Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KRBPKiromic BioPharma Inc
24/04/202414h08Business WireKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsNASDAQ:KRBPKiromic BioPharma Inc
19/04/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
10/04/202422h30Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:KRBPKiromic BioPharma Inc
05/04/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
02/04/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
02/04/202414h18Business WireKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
21/03/202422h21Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:KRBPKiromic BioPharma Inc
20/03/202422h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
20/03/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
19/03/202413h08Business WireEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
01/03/202414h08Business WireKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialNASDAQ:KRBPKiromic BioPharma Inc
29/02/202400h30Business WireKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thNASDAQ:KRBPKiromic BioPharma Inc
28/02/202422h09GlobeNewswire Inc.Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thNASDAQ:KRBPKiromic BioPharma Inc
14/02/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
14/02/202414h08Business WireResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsNASDAQ:KRBPKiromic BioPharma Inc
29/01/202413h47Business WireKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
11/01/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
05/01/202414h08Business WireKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
14/12/202314h17Business Wire Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
09/11/202315h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
13/09/202322h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
13/09/202322h35Business WireKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14NASDAQ:KRBPKiromic BioPharma Inc
29/08/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:KRBP

Kürzlich von Ihnen besucht

DBI
SDXP
SDAX
TG
CBK
Commerzbank
NASDAQ
NVDA
NVIDIA
DBI
MDAX
MDAX
TG
DTE
Deutsche Telekom
TG
NOV
Novo Nordisk
AMEX
SPY
SPDR S&P 500
TG
BAYN
Bayer
NASDAQ
MSFT
Microsoft
CCOM
US30
US 30
PM
XAUUSD
Gold vs US Dollar
FX
EURUSD
Euro vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten